Relay Therapeutics Inc Insider Trading
Every director, officer and 10% holder of Relay Therapeutics Inc has to report each trade in its stock within two business days of making it. This is those filings.
RLAY on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Sanjiv PatelPresident and CEO2026-10-0748.2K shat $18.10 | Sale10b5-1 plan | $872.4K |
| Thomas CatinazzoChief Financial Officer2026-10-0617.5K shat $18.58 | Sale10b5-1 plan | $325.4K |
| Thomas CatinazzoChief Financial Officer2026-10-06206 shat $19.26 | Sale10b5-1 plan | $4K |
| Donald A BergstromPresident, R&D2026-09-088.5K shat $18.97 | Sale10b5-1 plan | $161.8K |
| Thomas CatinazzoChief Financial Officer2026-09-0817.7K shat $18.94 | Sale10b5-1 plan | $335.6K |
| Sanjiv PatelPresident and CEO2026-09-0848.2K shat $18.94 | Sale10b5-1 plan | $912.9K |
| Peter RahmerSee remarks2026-08-264.5K shat $20.03 | Sale10b5-1 plan | $90.3K |
| SVF Pauling Ltd10% owner2026-08-256M shat $19.40 | Sale | $116.4M |
| Sanjiv PatelPresident and CEO2026-08-1748.2K shat $20.33 | Sale10b5-1 plan | $979.9K |
| Thomas CatinazzoChief Financial Officer2026-08-1417.7K shat $19.74 | Sale10b5-1 plan | $349.7K |
| Thomas CatinazzoChief Financial Officer2026-07-281.5K shat $18.61 | Sale | $27.2K |
| Peter RahmerSee remarks2026-07-28748 shat $18.61 | Sale | $13.9K |
| Donald A BergstromPresident, R&D2026-07-282.2K shat $18.61 | Sale | $41.6K |
| Sanjiv PatelPresident and CEO2026-07-0748.2K shat $19.58 | Sale10b5-1 plan | $943.7K |
| Donald A BergstromPresident, R&D2026-07-068.7K shat $18.71 | Sale10b5-1 plan | $162K |
| Thomas CatinazzoChief Financial Officer2026-07-0617.7K shat $18.69 | Sale10b5-1 plan | $331.1K |
| Peter RahmerSee remarks2026-06-3050K shat $19.09 | Sale10b5-1 plan | $954.5K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on RLAY
Follow Relay Therapeutics Inc (RLAY) by email
New trades in Relay Therapeutics Inc (RLAY) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.